Disruption of Laminin-Integrin-CD151-Focal Adhesion Kinase Axis Sensitizes Breast Cancer Cells to ErbB2 Antagonists
Yang XH, Flores LM, Li Q, Zhou P, Xu F, Krop IE, Hemler ME. Disruption of Laminin-Integrin-CD151-Focal Adhesion Kinase Axis Sensitizes Breast Cancer Cells to ErbB2 Antagonists. Cancer Research 2010, 70: 2256-2263. PMID: 20197472, PMCID: PMC3310185, DOI: 10.1158/0008-5472.can-09-4032.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntigens, CDAntineoplastic AgentsBreast NeoplasmsCell Adhesion MoleculesCell Line, TumorDrug SynergismEnzyme ActivationFocal Adhesion Protein-Tyrosine KinasesHumansIntegrin alpha3beta1Integrin alpha6beta4LapatinibProtein Kinase InhibitorsQuinazolinesReceptor, ErbB-2Signal TransductionTetraspanin 24TrastuzumabConceptsAnti-ErbB2 agentsBreast cancer cellsHuman ErbB2Cancer cellsSensitizes breast cancer cellsTetraspanin protein CD151Mammary tumor cellsFocal adhesion kinaseLaminin-5ErbB2 antagonistTrastuzumab treatmentBreast cancerLaminin-binding integrinsDrug resistanceTumor cellsCD151 knockdownLaminin-integrinErbB2TrastuzumabCancerCD151CellsTreatmentKnockdownAgents